Burning Rock's STELLA shows 65.9% sensitivity, 97.2% specificity in breast lesion study
BNR•Burning Rock Biotech presented STELLA breast lesion study results showing 65.9% sensitivity and 97.2% specificity in a 516-patient study.
1. Study results
Burning Rock Biotech presented clinical validation results for STELLA at the ESMO Congress on October 27, 2026. The 516-patient PERCEIVE-BREAST study showed potential for the test to help distinguish malignant from benign breast lesions alongside conventional imaging; detection improved with disease stage. Negative results alone cannot rule out malignancy, and follow-up imaging and pathological examination are required.
